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Purpose: The purpose of this study was to determine whether interleukin (IL)-4 genetic variants are
associated with age-related macular degeneration (AMD).
Methods: The genotyping of IL-4 -590 and intron 3 variable number of tandem repeats (VNTR) was
conducted for 171 patients with AMD and 134 controls by using TagMan and polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP) assays.
Results: There was no difference in distribution of age, sex, body mass index, and status of systemic
disease between AMD patients and healthy controls. Signiﬁcantly, more patients were current smokers in
the AMD group compared with the controls (p¼ 0.038). The genotypes of IL-4 -590 and intron 3 VNTR
were associated with the risk of AMD in our results. In the stratiﬁcation analysis, both IL-4 -590 allelic
type and smoking status were independently associated with AMD. No interactions between allelic type
and smoking were found to contribute to risk of AMD. The mean AMD score was signiﬁcantly higher in
carriers with IL-4 -590 T/T or T/C genotypes compared with those with C/C.
Conclusions: Our results support the hypothesis that polymorphisms of IL-4 -590 and intron 3 VNTR
might be a genetic marker for the development of AMD.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Age-related macular degeneration (AMD) is an important cause
of loss of vision as people age.1 The exact pathogenesis of AMD is not
known. A number of possible mechanisms have been postulated,
including genetic, vascular, Bruch membrane permeability abnor-
malities, photo-oxidative damage, and increased growth factors or
cytokines. Varieties of risk factors for AMD have been incriminated
from various epidemiologic studies, suggesting that the condition
is multifactorial in etiology involving genetic and environmental
factors. The risk factors include age, race/ethnicity, heredity,
smoking, sex, socioeconomic status, iris color, macular pigment
density, cataract and its surgery, refractive error, cup/disk ratio,
cardiovascular disease, hypertension and blood pressure, serum
lipid level and dietary fat intake, body mass index hematological
factors, reproductive and related factors, dermal elastoticeral Hospital, Number 386,
e Ophthalmologic Society of Taiwdegeneration, antioxidant enzyme, sunlight exposure, micro-
nutrients, dietary ﬁsh intake, and alcohol consumption.2
Although studies regarding the roles of major genes associated
with AMD in different populations bloomed recently, there was no
conclusion about the exact pathogenesis of AMD.3,4 Increasing
evidence suggests the role of inﬂammation in AMD.5,6 The rela-
tionship between AMD and inﬂammation further supports genetic
studies to identify inﬂammation-associated single nucleotide
polymorphisms (SNPs) that modulate AMD risk. These SNPs focus
on gene encoding complement factors, chemokines and chemokine
receptors, and toll-like receptors.7e15
Interleukins (ILs) help mediate many of the effector phases of
immune and inﬂammatory response. Several ILs, including IL-6, -8
and -10 have been found to be associated with AMD.10,15e18 IL-4 is
a key cytokine in humoral and adaptive immunity. A SNP located
at -590 has been reported to affect its transcriptional activity.
Previous studies demonstrated that T allele is correlated with
higher level of serum IL-4, whereas the C allele is correlated with
lower level of serum IL-4.19,20 Another polymorphism which is
composed of a variable number of tandem repeats (VNTR) of a 70-
bp sequence and is located within the third intron of the IL-4 gene
may also inﬂuence the production of IL-4.21 Recent studies on thean. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Basic available demographic characteristics of the study population.
Factor/category AMD Control p value
n¼ 1 71 (%) n¼ 134 (%)
Age (yrs), mean SD 73.98 9.35 73.45 9.88 0.633
 65 36 (21.1) 32 (23.9) 0.776
66e75 47 (27.5) 33 (24.6)
> 75 88 (51.5) 69 (51.5)
Sex 0.882
Women 31 (18.1) 26 (19.4)
Men 140 (81.9) 108 (80.6)
BMI, Mean SD 23.76 3.13 23.96 3.03 0.576
 18.5 7 (4.1) 3 (2.2) 0.454
18.6e24 85 (49.7) 75 (56.0)
> 24 79 (46.2) 56 (41.8)
Smoking status 0.038
Current smoker 55 (32.2) 28 (20.9)
Not a current smoker 116 (67.8) 106 (79.1)
Systemic disease
Hypertension 61 (35.7) 53 (39.6) 0.551
Diabetes mellitus 17 (9.9) 21 (15.7) 0.162
CADs 22 (12.9) 21 (15.7) 0.511
AMD¼ age-related macular degeneration; BMI¼ body mass index; CAD¼
cardiovascular disease; SD¼ standard deviation.
p values were estimated by Fisher’s Exact test.
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although a report has showed that it might be related to the ocular
surface inﬂammatory disorders.22 In this report, we examine
IL-4 -590 T polymorphism with the development of AMD. The
inﬂuence on the severity of AMD was also analyzed.
2. Methods
We recruited 171 patients with AMD and 134 controls without
any fundus abnormality from the outpatient clinic of the Depart-
ment of Ophthalmology, Kaohsiung Veterans General Hospital. All
types of AMD patients were included. Care was taken to exclude
patients who reported any infective or autoimmune diseases, which
might interfere with the analysis. The fundus image and fundus
ﬂuorescent angiography were performed by using a digital fundus
camera (Visupac 450, Zeiss FF450, Germany). The grading of AMD
uses a simpliﬁed severity scale for AMD.23 The scale is based on the
presence or absence in each eye of two easily identiﬁed retinal
abnormalities, drusen and pigment abnormalities. The scoring
system assigns to each one risk factor for the presence of one or
more large drusen and one risk factor for the presence of any
pigment abnormality (dry AMD). For persons with neovascular
AMD, two risk factors are assigned to that eye (exudative AMD). Risk
factors are then summed up across both eyes, yielding a ﬁve-step
scale (0e4). Recruited patients were older than 55 and have any
subtypes of AMD. The healthy controls without any fundus abnor-
mality were from out patient clinic and frequency-matched to case
patients on age ( 5 years) and sex. In addition to blood sampling, all
patients were asked to complete a questionnaire regarding demo-
graphic data and modiﬁable lifestyle factors. Informed consent was
obtained from all participants by way of a consent form approved by
the Institutional Review Board for Human Research of Kaohsiung
Veterans General Hospital. The procedures used conformed to the
tenets of the Declaration of Helsinki.
2.1. Polymorphism genotyping
Genomic DNA was extracted and puriﬁed from buffy coat cells
using QIAamp DNA blood Midi kit according to the manufacture’s
instructions (Qiagen Sciences, Germantown, MD, USA). The detec-
tion of genotypes of single nucleotide polymorphisms in IL-4 -590
(rs2243250) were performed by the TagMan real-time polymerase
chain reaction (RT-PCR) method (Applied Biosystems, Foster City,
CA, USA), and then analyzed by the ABI PRISM 7500 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA) in
a 96-well format. PCR reactions were carried out in reaction mixes
containing 10 ng DNA, 5 ml 2 TagMan Universal PCR Master Mix
(Applied Biosystems), 0.5 ml 20 Primer/Probe mixture, and
ddH2O to a ﬁnal volume of 10 ml. The PCR programwas as follows:
95C for 10 minutes, followed by 40 cycles of 15 seconds at 92C,
and 1 minute at 60C. One no template control (NTC) in each 96-
well format was used for quality-control procedures. The allelic-
speciﬁc ﬂuorescence data from each plate were analyzed using
SDS v1.3.1 software (Applied Biosystems) to automatically deter-
mine the genotype of each sample.
The VNTR of IL-4 intron 3 was determined by PCR-based assay
with primers already described, 50-AGGCTGAAAGGGGGAAAGC-30
and 50-CTGTTCACCTCAACTGCTCC-30.24 The PCR reaction was per-
formed in a 20-ml reaction mixture containing 1 PCR buffer
(10 mM KCl, 2 mM MgSO4, 20 mM Tris-HCl (pH 8.8), 0.1% Triton X-
100, 10 mM (NH4)2SO4 and 0.1 mg/ml BSA), 0.1 mM dNTPs, 0.1 mM
each forward and reverse PCR primers, and 0.5 units Taq poly-
merase (Yeastern Biotech Co., Ltd, Taipei, Taiwan). The PCR cycling
conditions for ampliﬁcation of polymorphism in intron 3 VNTRwas
95C for 5 minutes, followed by 30 cycles at 95C for 30 seconds,58C for 45 seconds, 72C for 45 seconds, and a ﬁnal extension step
at 72C for 10 minutes. Then, the PCR products were separated by
2.5% agarose gels containing ethidium bromide for 15 minutes at
150 V. The separated DNA fragments for VNTR polymorphismwere
183 bp (two 70-bp repeats) and 253 bp (three 70-bp repeats) for
RP1 and RP2 alleles, respectively.
The quality-control procedures are implemented to ensure high
genotyping accuracy in our laboratory. A sample of each genotype
assayed by polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) was randomly selected for DNA
sequencing to verify the allele sequence and the results were 100%
concordant to the initial analysis. Next, 5% of the random samples of
each genotype were repeated for each locus, and the results were
100% concordant to the initial analysis.
2.2. Statistical analysis
All genotype frequencies in each population were tested for
deviation from the Hardy-Weinberg equilibrium by the c2 test. The
genotype frequencies for each polymorphism were determined by
direct counting, and the allele and allele carriage frequencies were
calculated. Differences in genotype frequencies between case and
control participants were analyzed with a 2  3 unisquare with 2
degrees of freedom. The allele and allele carriage frequency were
compared with a 2  2c2 test. Statistical analysis was performed
usingc2 contingency table analysis for all categorical data of clinical
phenotypes and laboratory variables, depending on the appropriate
number of degrees of freedom. The Fisher exact test was used if any
expected frequency was lower than ﬁve. The false discovery rate
(FDR) was applied for a p value correction for multiple comparisons
of all allelic or genotypic types. The calculation of FDR was done
following the protocol described previously.25 Brieﬂy, the procedure
runs as following: Starting from the smallest p value p(1), compare
each p(i) with h(i)¼minute (0.05, 0.05 xm/(mþ 1-i)2). Reject the
hypothesis corresponding to p(i) if it is smaller than or equal to the
threshold h(1), and continue to reject the hypothesis as long as p(i) is
less than or equal to h(i). Stopwhen p(k)> h(k) for theﬁrst time. Reject
all of the hypotheses corresponding to the smallest k-1 p values.
Student’s t-test was used to compare the means of the continuous
variables, such as age. A p value < 0.05 was considered signiﬁcant.
Table 2
Distribution and odds ratios for patients with AMD and controls.
AMD (n¼ 171) Control (n¼ 134) COR AOR
Number (%) Number (%) (95% CI) p pcorrected (95% CI) p pcorrected
IL-4 -590
C/C 5 (2.9) 14 (10.4) 1 1
T/C 58 (33.9) 46 (34.3) 3.53 (1.19w10.52) 0.024 0.032 3.19 (1.06w9.59) 0.039 0.039
T/T 108 (63.2) 74 (55.3) 4.09 (1.41w11.83) 0.009 0.036 3.71 (1.27w10.83) 0.017 0.068
C/C 5 (2.9) 14 (10.4) 1 1
T/CþT/T 166 (97.1) 120 (89.6) 3.87 (1.36w11.04) 0.011 0.022 3.51 (1.22w10.09) 0.020 0.040
C allele frequency 68 (19.9) 74 (27.6) 1 1
T allele frequency 274 (80.1) 194 (72.4) 1.54 (1.05w2.24) 0.025 0.050 1.50 (1.03w2.20) 0.037 0.074
IL-4 intron 3 VNTR
RP2/RP2 2 (1.2) 9 (6.7) 1 1
RP1/RP2 61 (35.7) 43 (32.1) 6.38 (1.31w31.03) 0.022 0.044 5.92 (1.21w29.03) 0.028 0.056
RP1/RP1 (63.2) 82 (61.2) 5.93 (1.25w28.17) 0.025 0.025 5.36 (1.12w25.74) 0.036 0.048
RP2/RP2 2 (1.2) 9 (6.7) 1 1
RP1/RP2þRP1þRP1 169 (98.8) 125 (93.3) 6.08 (1.29w28.65) 0.022 0.022 5.56 (1.17w26.43) 0.031 0.031
RP2 allele frequency 65 (19.0) 61 (22.8) 1 1
RP1 allele frequency 277 (81.0) 207 (77.2) 1.26 (0.85w1.86) 0.256 0.256 1.21 (0.82w1.81) 0.341 0.341
AMD¼ age-related macular degeneration; AOR¼ adjusted odds ratio; COR¼ crude odds ratio.
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A total of 171 patients with AMD and 134 matched controls
were recruited for the polymorphism study. Baseline patient
demographics are summarized in Table 1. There was no difference
in age, age distribution, and sex between patients with AMD and
controls. Signiﬁcantly more patients were current smokers in the
AMD group than the control (p¼ 0.038). Other factors such as body
mass index (BMI), hypertension, diabetes mellitus, and cardiovas-
cular disease did not differ signiﬁcantly between groups. Among
controls, the genotype distributions were in Hardy-Weinberg
equilibrium. The p values were 0.102 for IL-4 -590 and 0.312 for
IL-4 intron 3 VNTR.
The allelic and genotypic type frequencies of the IL-4 -590 and
intron 3 VNTR in patients with AMD and controls are shown in
Table 2. At locus -590 T > C, an increased risk was found for T allele
[adjusted odds ratio (AOR)¼ 1.50, 95% conﬁdence intervals (CI):
1.03e2.20], T/C genotype (AOR¼ 3.19, 95% CI: 1.06e9.59), T/T
genotype (AOR¼ 3.71, 95% CI: 1.27e10.83), and combined T/Cþ C/C
genotype (AOR¼ 3.51, 95% CI: 1.22e10.09); however, only T/C
genotype and the combined T/C þ T/T genotype reach statistical
signiﬁcances after FDR correction. At locus intron 3 VNTR, no
signiﬁcant association was found between allelic type and risk of
AMD. RP1/RP2 genotype (AOR¼ 5.92, 95% CI: 1.21e29.03), RP1/RP1
genotype (AOR¼ 5.36, 95% CI: 1.12e25.74) and combined RP1/
RP2 þ RP1/RP1 genotype (AOR¼ 5.56, 95% CI: 1.17e26.43) were
correlated with the increased risk of AMD, even after FDR correc-
tion, except for the RP1/RP2 genotype.
Modest linkage disequilibrium (LD) was observed between
the polymorphisms at locus -590 and locus VNTR in intron 3
(D0 ¼ 0.892). The frequencies of C-RP1, C-RP2, T-RP1, and T-RP2
haplotypes were 2.9%, 17.0 %, 78.1%, and 2.0%, respectively, in AMD
cases and 6.0%, 21.6%, 71.3%, and 1.1% in controls, respectively. No
associations between the two-locus haplotypes and AMD risk wereTable 3
Odds ratios for AMD according allelic type of IL-4-590 and smoking status.
Allelic type (IL-4 -590) Smoking AMD Control CO
Number (%) Number (%) (95% CI)
C No 46 (13.5) 64 (23.9) 1
T No 186 (54.4) 148 (55.2) 1.75 (1.13w2.70)
C Yes 22 (6.4) 10 (3.7) 3.06 (1.32w7.08)
T Yes 88 (25.7) 46 (17.2) 2.66 (1.58w4.48)
AMD¼ age-related macular degeneration; AOR¼ adjusted odds ratio; COR¼ crude oddsfound (data not shown). In the stratiﬁcation analysis, we found that
people who carried T allele are more susceptible to develop AMD
than controls even if they were (AOR¼ 2.76, 95% CI: 1.62e4.70,
pcorrected < 0.001) or were not (AOR¼ 1.74, 95% CI: 1.13e2.70,
pcorrected¼ 0.013) current smokers (Table 3). It means that no
interactions between allelic type and smoking status were found to
contribute to risk of AMD. These results might suggest that smoking
was an important risk factor for AMD, but it cannot modulate the
effect of the allelic type of IL-4 -590 on risk of AMD.
We further looked at the inﬂuence of the IL-4 -590 genotype on
the severity of AMD. In patients with AMD, the mean AMD score of
patients with IL-4 e590 T/T or T/C were signiﬁcantly higher than
those with IL-4 e590 C/C (C/C: 3.0 0.7, T/C: 3.71.0, T/T:
3.51.1; T/C vs. C/C, p¼ 0.018; T/T vs. C/C, p¼ 0.010). Patients with
AMD and IL-4 -590 C/C were mostly in the less severe group of
AMD (Fig. 1).
4. Discussion
Our study showed that genotypic types of IL-4 -590 and intron 3
VNTR are associated with the risk of AMD in Taiwanese adults. IL-4
-590 T/C genotype and the combined T/C þ C/C genotype are
associated with the increased risk for AMD. The RP1/RP1 genotype
and combined RP1/RP2 þ RP1/RP1 genotype were associated with
the increased risk of AMD. In addition, the mean AMD score was
signiﬁcantly higher in carriers with IL-4 -590 T/T or T/C genotypes
compared with those with C/C. Our results support the hypothesis
that inﬂammation plays an important role in the development and
progress of AMD.
IL-4 is a key cytokine that induce the activation and differenti-
ation of B cells as well as the development of the Th2 subset of
lymphocytes.26 IL4 has effects not only on hematopoietic cells,
including cells of innate and adaptive immune system, but also on
a variety of structural cells. For example, it can potentiateR AOR p for interaction
p value pcorrected (95% CI) p value pcorrected
1 0.164
0.012 0.012 1.74 (1.13w2.70) 0.013 0.013
0.009 0.014 3.09 (1.33w7.18) 0.009 0.014
< 0.001 < 0.001 2.76 (1.62w4.70) < 0.001 < 0.001
ratio.
Fig. 1. Association of IL-4 -590 genotype and the severity of AMD. Patients with T allele
tend to have exudative AMD in at least one eye. AMD¼ age-related macular degen-
eration; IL¼ interleukin.
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vascular cell adhesion molecule-1, which is a cell surface glyco-
protein expressed by cytokine-activated endothelium that medi-
ates the adhesion of monocytes and lymphocytes, which induce
vascular inﬂammation.29 Therefore, it is found as a mitogen for
both microvascular capillary and large vessel.
There are two common polymorphisms in the IL-4 gene, -590
C/T and a 70-bp sequence variable number tandem repeat at intron
3, and many minor polymorphisms, such as -168, -33, 3437, 3557,
4047, 4144, 4271, 4367, and 8427.30 The IL-4 -590 polymorphism is
located upstream of all known control elements of IL-4, such as the
negative regulatory element, the Nucleosome-free regions (NF-r)
recognition sequence, and the Goldberg-Hogness box (TATA box).31
Both the C to T exchange at position -590 and RP1 allele at VNTR
have been shown to enhance IL-4 production or activity by T
cells.20,30 The rare RP2 allele for IL-4 intron 3 is a protective factor
for joint destruction in patients with rheumatoid arthritis.32 AMD is
considered to be a complex genetic disease in which there are
multiple genetic effects interacting with the environment to
modify the susceptibility and severity of this disease. The immune
system has been strongly implicated as a contributor to the path-
ogenesis of AMD. Many of the components of drusen are known
immune and inﬂammatory factors. In our results, IL-4 -590T/T
might play a role in AMD development and progress. It supported
the association between inﬂammation and AMD. Recently, some
studies have suggested a potential role for chlamydia pneumoniae
infection in AMD pathogenesis.18,33 It is reported that the presence
of risk-conferring CHF a complement factor H (CFH) variant and
high C pneumoniae antibody titer signiﬁcantly increased AMD
risk.34 It is possible that people carry IL-4 -590 T allele might over-
react to pathogens or any external stimuli followed by persistent
low-grade inﬂammation, and then predispose to AMD.
Several ILs, including IL-6, -8 and -10 have been found to be
associated with AMD.10,15e18 The AA genotype of IL-8 A251 and IL-8
C781T variant had been reported to increase risk of developing
AMD. IL-10 was found to suppress or inhibit choroidal neo-
vascularization by regulating macrophage activity in animal model
and was proposed to be an attractive therapeutic target for AMD.16
Our study showed the signiﬁcant association of IL-4 -590 with
AMD, which might help when investigating the pathogenesis and
management of AMD. IL-4 -590 might be a genetic marker for the
development of AMD.
Despite these ﬁndings, there are limitations to this study that
are worth noting. This was a single-center cohort investigation of
patients in southern Taiwan. The sample sizewas limited. In genetic
study, large sample size is important to prevent false positive
results. However, we couldn’t recruit more samples in our study
because of our limited resources. Although FDR can not guarantee
to prevent false-positive results, it is suggested as a practicalmethod to control false discoveries in genetic study.35 Our ﬁndings
about IL-4 may be insufﬁcient to clarify the complex interplays
among a number of different genes controlling expression of
cytokine in AMD. Therefore, replication studies with independent
large cohorts are needed.
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